skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 2,963  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative
Material Type:
Article
Add to My Research

The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative

Toxicological sciences, 2014-12, Vol.142 (2), p.427-435 [Peer Reviewed Journal]

The Author 2014. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. ;ISSN: 1096-6080 ;EISSN: 1096-0929 ;DOI: 10.1093/toxsci/kfu198 ;PMID: 25246669

Full text available

2
A product of independent beta probabilities dose escalation design for dual-agent phase I trials
Material Type:
Article
Add to My Research

A product of independent beta probabilities dose escalation design for dual-agent phase I trials

Statistics in medicine, 2015-04, Vol.34 (8), p.1261-1276 [Peer Reviewed Journal]

2015 The Authors. Published by John Wiley & Sons Ltd. ;2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. ;2015 The Authors. Published by John Wiley & Sons Ltd. 2015 ;ISSN: 0277-6715 ;EISSN: 1097-0258 ;DOI: 10.1002/sim.6434 ;PMID: 25630638 ;CODEN: SMEDDA

Full text available

3
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Material Type:
Article
Add to My Research

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

Journal of clinical oncology, 2017-03, Vol.35 (7), p.785-792 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2015.66.1389 ;PMID: 28068177

Full text available

4
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment
Material Type:
Article
Add to My Research

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment

Journal of clinical oncology, 2015-01, Vol.33 (3), p.278-284 [Peer Reviewed Journal]

2014 by American Society of Clinical Oncology 2014 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2014.58.2635 ;PMID: 25512456

Full text available

5
The COVID-19 vaccine development landscape
Material Type:
Article
Add to My Research

The COVID-19 vaccine development landscape

Nature reviews. Drug discovery, 2020-05, Vol.19 (5), p.305-306 [Peer Reviewed Journal]

COPYRIGHT 2020 Nature Publishing Group ;Nature 2020. ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/d41573-020-00073-5 ;PMID: 32273591

Full text available

6
Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials
Material Type:
Article
Add to My Research

Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials

British journal of cancer, 2020-11, Vol.123 (10), p.1496-1501 [Peer Reviewed Journal]

The Author(s), under exclusive licence to Cancer Research UK 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s), under exclusive licence to Cancer Research UK 2020 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-020-01033-x ;PMID: 32868897

Full text available

7
Embracing model-based designs for dose-finding trials
Material Type:
Article
Add to My Research

Embracing model-based designs for dose-finding trials

British journal of cancer, 2017-07, Vol.117 (3), p.332-339 [Peer Reviewed Journal]

Copyright Nature Publishing Group Jul 25, 2017 ;Copyright © 2017 The Author(s) 2017 The Author(s) ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.2017.186 ;PMID: 28664918

Full text available

8
FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
Material Type:
Article
Add to My Research

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC

Clinical cancer research, 2022-04, Vol.28 (8), p.1482-1486 [Peer Reviewed Journal]

2021 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-21-3074 ;PMID: 34903582

Full text available

9
Commentary on the EMA Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products
Material Type:
Article
Add to My Research

Commentary on the EMA Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products

British journal of clinical pharmacology, 2018-07, Vol.84 (7), p.1401-1409 [Peer Reviewed Journal]

2018 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. ;2018 The British Pharmacological Society ;ISSN: 0306-5251 ;EISSN: 1365-2125 ;DOI: 10.1111/bcp.13550 ;PMID: 29451320

Full text available

10
Genome-editing Technologies for Gene and Cell Therapy
Material Type:
Article
Add to My Research

Genome-editing Technologies for Gene and Cell Therapy

Molecular therapy, 2016-03, Vol.24 (3), p.430-446 [Peer Reviewed Journal]

2016 Official journal of the American Society of Gene & Cell Therapy ;Copyright Nature Publishing Group Mar 2016 ;Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy 2016 Official journal of the American Society of Gene & Cell Therapy ;ISSN: 1525-0016 ;EISSN: 1525-0024 ;DOI: 10.1038/mt.2016.10 ;PMID: 26755333

Full text available

11
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
Material Type:
Article
Add to My Research

Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy

Clinical cancer research, 2016-07, Vol.22 (14), p.3425-3431 [Peer Reviewed Journal]

2016 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-15-2428 ;PMID: 27208063

Full text available

12
Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding
Material Type:
Article
Add to My Research

Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding

Annals of oncology, 2018-03, Vol.29 (3), p.694-699 [Peer Reviewed Journal]

2017 THE AUTHORS ;The Author(s) 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2017 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdx795 ;PMID: 29267863

Full text available

13
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Material Type:
Article
Add to My Research

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Clinical cancer research, 2017-04, Vol.23 (8), p.1920-1928 [Peer Reviewed Journal]

2016 American Association for Cancer Research. ;Copyright American Association for Cancer Research Inc Apr 15, 2017 ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-16-1741 ;PMID: 27827313

Full text available

14
Scientists in the dark after French clinical trial proves fatal
Material Type:
Article
Add to My Research

Scientists in the dark after French clinical trial proves fatal

Nature (London), 2016-01, Vol.529 (7586), p.263-264 [Peer Reviewed Journal]

ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature.2016.19189 ;PMID: 26791697

Full text available

15
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Material Type:
Article
Add to My Research

Clinical experiences with systemically administered siRNA-based therapeutics in cancer

Nature reviews. Drug discovery, 2015-12, Vol.14 (12), p.843-856 [Peer Reviewed Journal]

COPYRIGHT 2015 Nature Publishing Group ;Copyright Nature Publishing Group Dec 2015 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd4685 ;PMID: 26567702

Full text available

16
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Material Type:
Article
Add to My Research

Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

Cancer cell, 2014-06, Vol.25 (6), p.846-859 [Peer Reviewed Journal]

2014 Elsevier Inc. ;Copyright © 2014 Elsevier Inc. All rights reserved. ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccr.2014.05.016 ;PMID: 24898549

Full text available

17
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
Material Type:
Article
Add to My Research

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

Journal of clinical oncology, 2018-03, Vol.36 (9), p.850-858 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2017.75.1644 ;PMID: 29341833

Full text available

18
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials
Material Type:
Article
Add to My Research

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials

Chest, 2017-08, Vol.152 (2), p.271-281 [Peer Reviewed Journal]

Copyright © 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. ;EISSN: 1931-3543 ;DOI: 10.1016/j.chest.2017.04.177 ;PMID: 28499515

Full text available

19
Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design
Material Type:
Article
Add to My Research

Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design

Clinical cancer research, 2014-09, Vol.20 (18), p.4758-4767 [Peer Reviewed Journal]

2014 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-13-2671 ;PMID: 25037736

Full text available

20
Antibody Drug Conjugates for Cancer Therapy
Material Type:
Article
Add to My Research

Antibody Drug Conjugates for Cancer Therapy

Pharmacological reviews, 2016-01, Vol.68 (1), p.3-19 [Peer Reviewed Journal]

Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics. ;ISSN: 0031-6997 ;EISSN: 1521-0081 ;DOI: 10.1124/pr.114.009373 ;PMID: 26589413

Full text available

Results 1 - 20 of 2,963  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (2,750)

Refine My Results

Creation Date 

From To
  1. Before 1997  (236)
  2. 1997 To 2002  (410)
  3. 2003 To 2008  (604)
  4. 2009 To 2015  (997)
  5. After 2015  (719)
  6. More options open sub menu

Language 

  1. English  (2,902)
  2. Japanese  (444)
  3. French  (30)
  4. German  (20)
  5. Spanish  (10)
  6. Portuguese  (7)
  7. Swedish  (2)
  8. Norwegian  (2)
  9. Italian  (1)
  10. Chinese  (1)
  11. More options open sub menu

Searching Remote Databases, Please Wait